NXTC NextCure Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: NXTC

Price (delayed)

$1.49

Market cap

$41.68M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.28

Enterprise value

$29.1M

NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases. Through its proprietary FIND-IO™ platform, NextCure studies various immune ...

Highlights
NXTC's debt is down by 10% year-on-year and by 3% since the previous quarter
The EPS has grown by 10% YoY
The quick ratio has plunged by 57% YoY and by 36% from the previous quarter
NextCure's equity has decreased by 36% YoY and by 13% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.nextcure.com
Peers: OMER OMGA

Key stats

What are the main financial stats of NXTC
Market
Shares outstanding
27.97M
Market cap
$41.68M
Enterprise value
$29.1M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.42
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$63.73M
EBITDA
-$59.65M
Free cash flow
-$51.41M
Per share
EPS
-$2.28
Free cash flow per share
-$1.84
Book value per share
$3.55
Revenue per share
$0
TBVPS
$4.13
Balance sheet
Total assets
$115.16M
Total liabilities
$16.11M
Debt
$5.77M
Equity
$99.05M
Working capital
$92.97M
Liquidity
Debt to equity
0.06
Current ratio
10.7
Quick ratio
10.02
Net debt/EBITDA
0.21
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-47.5%
Return on equity
-53.3%
Return on invested capital
-55.8%
Return on capital employed
-60.4%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

NXTC stock price

How has the NextCure stock price performed over time
Intraday
8.76%
1 week
15.5%
1 month
-40.16%
1 year
-1.97%
YTD
30.7%
QTD
-33.18%

Financial performance

How have NextCure's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$68.87M
Net income
-$63.73M
Gross margin
N/A
Net margin
N/A
NXTC's net income is up by 9% year-on-year
NextCure's operating income has increased by 4.6% YoY

Growth

What is NextCure's growth rate over time

Valuation

What is NextCure stock price valuation
P/E
N/A
P/B
0.42
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has grown by 10% YoY
The P/B is 65% lower than the 5-year quarterly average of 1.2 but 5% higher than the last 4 quarters average of 0.4
NextCure's equity has decreased by 36% YoY and by 13% QoQ

Efficiency

How efficient is NextCure business performance
NXTC's return on equity is down by 33% year-on-year and by 13% since the previous quarter
NXTC's ROA is down by 27% YoY and by 12% QoQ
NextCure's return on invested capital has decreased by 23% YoY and by 12% QoQ

Dividends

What is NXTC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NXTC.

Financial health

How did NextCure financials performed over time
The quick ratio has plunged by 57% YoY and by 36% from the previous quarter
NXTC's current ratio has dropped by 55% year-on-year and by 35% since the previous quarter
NXTC's debt is 94% smaller than its equity
The debt to equity has surged by 50% year-on-year and by 20% since the previous quarter
NextCure's equity has decreased by 36% YoY and by 13% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.